Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer.
David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Articles by David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Latest Updated Articles
- Capecitabine/Irinotecan Combination Regimens in Colorectal Cancer
Published: April 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
2
ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma
3
Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer
4
212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs
5
